



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Inetetamab

Cat. No.:	HY-P99969
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities ^{[1][2]} .									
IC₅₀ & Target	HER2									
In Vivo	<p>Inetetamab (20 mg/kg, i.p.) shows antitumor effects in the JIMT-1 xenograft mouse model^[2].</p> <p>Inetetamab (20 mg/kg, i.p.) together with Pyrotinib or Cyclophosphamide also has distinct antitumor effects in JIMT-1 and NCI-N87 xenograft mouse model^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>JIMT-1 xenograft mouse model^[2]</td> </tr> <tr> <td>Dosage:</td> <td>20 mg/kg, or together with Pyrotinib (20 mg/kg, p.o.) or Cyclophosphamide (10 mg/kg, p.o.)</td> </tr> <tr> <td>Administration:</td> <td>i.p, twice a week</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth with a tumor growth inhibition (TGI) rate of approximately 40%, and induces a stronger synergistic antitumor effect with Pyrotinib or Cyclophosphamide.</td> </tr> </table>		Animal Model:	JIMT-1 xenograft mouse model ^[2]	Dosage:	20 mg/kg, or together with Pyrotinib (20 mg/kg, p.o.) or Cyclophosphamide (10 mg/kg, p.o.)	Administration:	i.p, twice a week	Result:	Inhibited tumor growth with a tumor growth inhibition (TGI) rate of approximately 40%, and induces a stronger synergistic antitumor effect with Pyrotinib or Cyclophosphamide.
Animal Model:	JIMT-1 xenograft mouse model ^[2]									
Dosage:	20 mg/kg, or together with Pyrotinib (20 mg/kg, p.o.) or Cyclophosphamide (10 mg/kg, p.o.)									
Administration:	i.p, twice a week									
Result:	Inhibited tumor growth with a tumor growth inhibition (TGI) rate of approximately 40%, and induces a stronger synergistic antitumor effect with Pyrotinib or Cyclophosphamide.									

REFERENCES

[1]. Min Yan, et al. Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: A single-arm, multicenter, phase 2 study. *Journal of Clinical Oncology*. 2022. 40 (16), e13030-e13030.

[2]. Deng L, et al. Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers. *Open Life Sci*. 2023 Jan 10;18(1):20220535.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA